/PODD
PODD Stock - Insulet Corporation
Healthcare|Medical - DevicesNASDAQ
$289.62-1.11%
$3.26 (-1.11%) • Dec 19
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.31
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.65
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+34.1%upside
Target: $388.38
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PODD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$286.72 – $292.52
TARGET (TP)$388.38
STOP LOSS$266.45
RISK/REWARD1:4.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.38
52W High$354.88
52W Low$230.05
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.07B | $1.70B | $1.31B | $1.10B | $904.40M |
| Gross Profit | $1.45B | $1.16B | $805.60M | $752.10M | $582.30M |
| Gross Margin | 69.8% | 68.3% | 61.7% | 68.4% | 64.4% |
| Operating Income | $308.90M | $220.00M | $37.60M | $126.00M | $51.50M |
| Net Income | $418.30M | $206.30M | $4.60M | $16.80M | $6.80M |
| Net Margin | 20.2% | 12.2% | 0.4% | 1.5% | 0.8% |
| EPS | $5.97 | $2.96 | $0.07 | $0.25 | $0.11 |
Company Overview
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
14
74%
Hold / Neutral
5
26%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
14 Bullish5 Neutral/Bearish
Price Targets
$300
Average Target
↑ 3.6% Upside
Now
$200
Low
$300
Average
$400
High
Based on 21 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 16th 2025 | Evercore ISI | Initiation | Outperform | $370 |
| November 19th 2025 | UBS | Upgrade | Buy | $400 |
| October 21st 2025 | Stifel | Resumed | Buy | $370 |
| September 8th 2025 | Oppenheimer | Resumed | Outperform | $365 |
| June 16th 2025 | Truist | Initiation | Buy | $365 |
| May 30th 2025 | Goldman | Initiation | Buy | $380 |
| May 13th 2025 | Wolfe Research | Upgrade | Outperform | $350 |
| April 29th 2025 | Wolfe Research | Downgrade | Peer Perform | - |
| March 6th 2025 | RBC Capital Mkts | Initiation | Outperform | $340 |
| November 6th 2024 | Bernstein | Initiation | Outperform | $300 |
| May 30th 2024 | Redburn Atlantic | Initiation | Buy | $235 |
| May 7th 2024 | Wolfe Research | Upgrade | Outperform | $200 |
| December 21st 2023 | Robert W. Baird | Upgrade | Outperform | $238← $180 |
| December 4th 2023 | Morgan Stanley | Upgrade | Overweight | $234← $185 |
| October 2nd 2023 | Jefferies | Upgrade | Buy | $240← $260 |
Earnings History & Surprises
PODDBeat Rate
78%
Last 18 quarters
Avg Surprise
+44.6%
EPS vs Estimate
Beats / Misses
14/4
Last 12 quarters
Latest EPS
$1.24
Q4 2025
EPS Surprise History
Q1 24
+112.1%
$1.40vs$0.66
Q2 24
+87.2%
$0.73vs$0.39
Q3 24
-2.5%
$0.55vs$0.56
Q4 24
+18.4%
$0.90vs$0.76
Q1 25
+15.0%
$1.15vs$1.00
Q2 25
+29.1%
$1.02vs$0.79
Q3 25
+27.2%
$1.17vs$0.92
Q4 25
+8.8%
$1.24vs$1.14
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 19, 2026 | $1.48 | — | — | — |
Q4 2025 | Nov 6, 2025 | $1.14 | $1.24 | +8.8% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $0.92 | $1.17 | +27.2% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $0.79 | $1.02 | +29.1% | ✓ BEAT |
Q1 2025 | Feb 20, 2025 | $1.00 | $1.15 | +15.0% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $0.76 | $0.90 | +18.4% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $0.56 | $0.55 | -2.5% | ✗ MISS |
Q2 2024 | May 9, 2024 | $0.39 | $0.73 | +87.2% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $0.66 | $1.40 | +112.1% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $0.40 | $0.71 | +77.5% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $0.26 | $0.38 | +46.2% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $0.09 | $0.23 | +155.6% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $0.24 | $0.55 | +129.2% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $0.17 | $0.45 | +164.7% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $0.21 | $-0.06 | -128.6% | ✗ MISS |
Q2 2022 | May 5, 2022 | $0.23 | $0.40 | +73.9% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | $0.32 | $0.42 | +31.2% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $0.24 | $0.18 | -25.0% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $0.12 | $0.10 | -16.7% | ✗ MISS |
Latest News
Truist Securities Maintains Buy on Insulet, Lowers Price Target to $390
📈 PositiveBenzinga•Dec 18, 2025, 02:27 PM
Canaccord Genuity Maintains Buy on Insulet, Raises Price Target to $450
📈 PositiveBenzinga•Dec 17, 2025, 08:06 PM•Also:
Evercore ISI Group Initiates Coverage On Insulet with Outperform Rating, Announces Price Target of $370
📈 PositiveBenzinga•Dec 16, 2025, 01:58 PM
Insulet Receives FDA 510(K) Clearance For Omnipod 5 Algorithm Enhancements Adding 100 Mg/DL Target Glucose And Improved Automated Mode, With U.S. Launch Anticipated In First Half Of 2026
📈 PositiveBenzinga•Dec 4, 2025, 12:07 PM
Canaccord Genuity Maintains Buy on Insulet, Raises Price Target to $432
📈 PositiveBenzinga•Nov 24, 2025, 02:52 PM•Also:
Insulet shares are trading higher after multiple analysts raised their price targets on the stock.
📈 PositiveBenzinga•Nov 21, 2025, 05:51 PM
Truist Securities Maintains Buy on Insulet, Raises Price Target to $412
📈 PositiveBenzinga•Nov 21, 2025, 05:25 PM
RBC Capital Maintains Outperform on Insulet, Raises Price Target to $380
📈 PositiveBenzinga•Nov 21, 2025, 02:39 PM
BTIG Maintains Buy on Insulet, Raises Price Target to $380
📈 PositiveBenzinga•Nov 21, 2025, 10:34 AM
Insulet drops on investor day as long-term outlook unveiled
📉 NegativeSeeking Alpha•Nov 20, 2025, 06:02 PM
Insulet Announces 2025–2028 Financial Outlook; Sees Revenue Projected To Grow At A CAGR Of ~20% At Constant Currency Rates, Driven By Continued Omnipod Adoption And Geographic Expansion; Adjusted Operating Margin Expected To Expand Annually By ~100 Basis Points, Reflecting Operational Efficiencies And Growing Scale; Adjusted Diluted EPS Anticipated To Grow At A CAGR Of 25%+; Free Cash Flow Forecast To Remain Strong, Enabling Disciplined Reinvestment In Innovation And Scaling Globally.
📈 PositiveBenzinga•Nov 20, 2025, 05:32 PM
Insulet shares are trading higher after UBS upgraded the stock from Neutral to Buy and raised its price target from $355 to $400.
📈 PositiveBenzinga•Nov 19, 2025, 04:08 PM•Also: ,
UBS Upgrades Insulet to Buy, Raises Price Target to $400
📈 PositiveBenzinga•Nov 19, 2025, 12:26 PM•Also: ,
BTIG Reiterates Buy on Insulet, Maintains $370 Price Target
📈 PositiveBenzinga•Nov 13, 2025, 10:42 AM
Watching Insulet; Shares See Volume To The Upside; Hearing Investor Business Daily SwingTrader Buys Stock
📈 PositiveBenzinga•Nov 12, 2025, 07:13 PM
Canaccord Genuity Maintains Buy on Insulet, Raises Price Target to $428
📈 PositiveBenzinga•Nov 7, 2025, 10:04 PM•Also:
RBC Capital Maintains Outperform on Insulet, Raises Price Target to $370
📈 PositiveBenzinga•Nov 7, 2025, 07:08 PM
Wells Fargo Maintains Overweight on Insulet, Raises Price Target to $360
📈 PositiveBenzinga•Nov 7, 2025, 06:45 PM
UBS Maintains Neutral on Insulet, Raises Price Target to $355
➖ NeutralBenzinga•Nov 7, 2025, 05:48 PM•Also:
Truist Securities Reiterates Buy on Insulet, Raises Price Target to $390
📈 PositiveBenzinga•Nov 7, 2025, 04:31 PM
Frequently Asked Questions about PODD
What is PODD's current stock price?
Insulet Corporation (PODD) is currently trading at $289.62 per share. The stock has moved -1.11% today.
What is the analyst price target for PODD?
The average analyst price target for PODD is $388.38, based on 1 analyst.
What sector is Insulet Corporation in?
Insulet Corporation operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is PODD's market cap?
Insulet Corporation has a market capitalization of $20.37 billion, making it a large-cap company.
Does PODD pay dividends?
No, Insulet Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBIIB
Biogen Inc.
$174.80
Mkt Cap: $25.6B
DGX
Quest Diagnostics Incorporated
$176.06
Mkt Cap: $19.7B
DXCM
DexCom, Inc.
$66.06
Mkt Cap: $25.8B
LH
Labcorp Holdings Inc.
$252.03
Mkt Cap: $20.9B
PHG
Koninklijke Philips N.V.
$26.66
Mkt Cap: $25.4B
SNN
Smith & Nephew plc
$32.82
Mkt Cap: $14.4B
STE
STERIS plc
$254.34
Mkt Cap: $25.0B
WAT
Waters Corporation
$378.03
Mkt Cap: $22.5B
WST
West Pharmaceutical Services, Inc.
$272.54
Mkt Cap: $19.6B
ZBH
Zimmer Biomet Holdings, Inc.
$89.13
Mkt Cap: $17.7B
Explore stocks similar to PODD for comparison